<DOC>
	<DOCNO>NCT00089219</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : This randomized phase I/II trial study three different dos vaccine compare see well work treat patient stage IIIB , stage IIIC , stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IIIB , Stage IIIC , Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine immune response patient stage IIIB , IIIC , IV melanoma treat vaccine comprise multiple synthetic melanoma peptide , Montanide ISA-51 , sargramostim ( GM-CSF ) . OUTLINE : This randomize study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive vaccine comprise low-dose multiple synthetic melanoma peptide , Montanide ISA-51 , sargramostim ( GM-CSF ) day 1 , 8 , 15 , 29 , 36 , 43 . - Arm II : Patients receive vaccine comprise medium-dose multiple synthetic melanoma peptide , Montanide ISA-51 , GM-CSF arm I . - Arm III : Patients receive vaccine comprise high-dose multiple synthetic melanoma peptide , Montanide ISA-51 , GM-CSF arm I . On day 22 , lymph node drain vaccination site remove determine whether immune system respond vaccine . PROJECTED ACCRUAL : A maximum 38 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage IIIB , IIIC , IV melanoma HLADR1 , DR4 , DR11 , DR13 , DR15 positive Brain metastasis allow discretion principle investigator PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm ^3 Hemoglobin &gt; 9 g/dL Hepatic Liver function test ≤ 2.5 time upper limit normal ( ULN ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No New York Heart Association class III IV heart disease Other Prior diagnosis cancer allow Not pregnant nursing Weight ≥ 110 pound No uncontrolled diabetes PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior growth factor More 4 week since prior allergy shot More 12 week since prior melanoma vaccine therapy* NOTE : *Prior melanoma vaccine allow patient disease progression administration vaccine No prior vaccination peptide use study Chemotherapy More 4 week since prior chemotherapy Endocrine therapy More 4 week since prior steroid Radiotherapy More 4 week since prior radiotherapy Surgery Not specify Other More 1 month since prior investigational drug therapies No concurrent investigational drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
</DOC>